Changes in Intended Management After 68Ga-PSMA-11 PET
| Treatment change | n | % |
| Major changes | 67 | 53.2 |
| Conversion to targeted treatment | 40 | 31.7 |
| ADT > RT | 12 | 9.5 |
| AS > RT | 10 | 7.9 |
| ADT > RT+ADT | 6 | 4.8 |
| AS > RT+ADT | 5 | 4.0 |
| Biopsy > RT | 2 | 1.6 |
| Biopsy > RT+ADT | 2 | 1.6 |
| Biopsy > cryoablation | 1 | 0.8 |
| RT+ADT > surgery | 1 | 0.8 |
| Sipuleucel-T > RT | 1 | 0.8 |
| Conversion to systemic treatment | 12 | 9.5 |
| AS > ADT | 5 | 4.0 |
| RT+ADT > ADT monotherapy | 2 | 1.6 |
| RT > ADT | 2 | 1.6 |
| AS > abiraterone | 1 | 0.8 |
| Surgery > ADT | 1 | 0.8 |
| Biopsy > ADT | 1 | 0.8 |
| Conversion to AS | 10 | 7.9 |
| RT+ADT > AS | 4 | 3.2 |
| ADT > AS | 4 | 3.2 |
| RT > AS | 2 | 1.6 |
| Miscellaneous | 5 | 4.0 |
| Surgery > RT+ADT | 2 | 1.6 |
| RT+ADT > cryoablation | 1 | 0.8 |
| RT+ADT > RT+ADT+chemotherapy | 1 | 0.8 |
| ADT > PSMA RLT | 1 | 0.8 |
| Minor changes | 8 | 6.4 |
| RT > RT+ADT | 5 | 4.0 |
| RT+ADT > RT | 3 | 2.4 |
ADT = androgen-deprivation therapy; AS = active surveillance; RLT = radioligand therapy.